NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism and DNA repair, with levels that do decline with age, a well-documented pattern across research, driving considerable interest in NAD+ precursor supplements as a longevity intervention, notably NMN, covered in its own dedicated supplement entry. This entry covers the broader NAD+-and-aging theory itself, worth separating what's reliably demonstrated from what remains an open question. The NMN entry covers the same biology from the product side.
- NAD+ levels genuinely decline with age, well-documented across research.
- NMN reliably raises blood NAD+ levels, this part is consistently demonstrated.
- Whether raised NAD+ translates to meaningful health outcomes is inconsistent across trials.
- Trials to date are small and short, nowhere near the evidence scale behind creatine or vitamin D3.
Reliable effect vs. open question
The biochemistry here is solid at two separate steps, NAD+ levels do decline with age, a consistent finding across research, and NAD+ precursor supplementation, NMN specifically, does reliably raise blood NAD+ levels back up in trials, a mechanistically clean, well-replicated effect at the level of the measured biomarker itself. This part of the story is on genuinely solid ground.
Where the evidence becomes less settled is the next, harder step, whether successfully raising NAD+ levels actually translates into the downstream health outcomes people care about, improved physical function, better metabolic health, extended healthspan. One 12-week randomized controlled trial found no significant improvement in arterial stiffness despite successfully raised NAD+ levels in the treatment group, while other, smaller trials found modest improvements in physical performance and sleep quality, an inconsistent picture. Trials conducted so far have also been small, roughly 36-108 participants, and short, 6-12 weeks, nowhere near the scale or duration of evidence behind considerably better-established interventions like creatine or vitamin D3.
| Claim | Evidence Status |
|---|---|
| NAD+ declines with age | Well-documented, consistent |
| NMN raises blood NAD+ levels | Reliably demonstrated |
| Raised NAD+ improves meaningful health outcomes | Inconsistent across small, short trials |
What precursor supplementation reliably does against what it has not been shown to do. The gap between the two columns is the whole question.
What NAD+ does, why it falls, and where the precursors act
NAD+ isn’t a supplement ingredient that happens to have a biological role. It is one of the most fundamental molecules in metabolism, which is exactly why the supplement category exists and why the outcome question is harder than it looks.
Two distinct jobs
- Electron carrier. NAD+ accepts electrons during glycolysis, the Krebs cycle and fatty acid oxidation, becoming NADH, then delivers them to the electron transport chain. Without recycling between the two forms, ATP production stops. This role is consumed and regenerated continuously, not used up.
- Substrate for signalling enzymes. This is where it is genuinely consumed. Sirtuins, PARPs and CD38 all cleave NAD+ as part of their function. PARPs consume it during DNA repair; sirtuins use it for deacetylation reactions implicated in metabolic regulation and mitochondrial function.
Why levels decline with age
Two processes, pulling in the same direction. Consumption rises: accumulating DNA damage increases PARP activity, and CD38 — an NAD-consuming enzyme expressed on immune cells — increases substantially with age and with chronic inflammation. Meanwhile salvage pathway efficiency, which recycles NAD+ from its breakdown products, appears to decline. Camacho-Pereira and colleagues established that in 2016, and it is the more interesting half of the story: the decline is driven by increased consumption rather than reduced synthesis alone, which points at a different intervention target.
Note what that implies. If CD38 activity is rising because of inflammaging, then falling NAD+ may be a consequence of the underlying process rather than a root cause of it. Supplementing the depleted molecule doesn’t necessarily address why it is being depleted.
The salvage pathway and where precursors enter
Most NAD+ in humans is recycled rather than synthesised from scratch. Nicotinamide is converted to NMN by the enzyme NAMPT — the rate-limiting step — and NMN is then converted to NAD+. Nicotinamide riboside enters upstream of NMN; NMN enters directly at that point.
This is the basis of the NR versus NMN argument, and it matters less than the marketing implies: both raise measurable NAD+ markers in human trials, and neither has demonstrated an advantage in outcomes.
What the human trials have and haven’t shown
Multiple randomised trials confirm oral precursors raise blood NAD+ metabolites, with good safety at studied doses. That part is settled. What remains unestablished is whether raising the level changes muscle function, insulin sensitivity, or anything a person would notice. Trials measuring those endpoints have been small and largely null or inconsistent.
The honest summary: a real decline, a real mechanism, a reliably raisable number, and no demonstrated outcome. That is a different claim from the one on the packaging.
Two claims that get conflated
Most health content treats “raises NAD+ levels” and “improves your health outcomes” as the same claim. The first is reliably true. The second is far less settled.
If you are considering an NAD+ precursor, understand that you are buying a demonstrated effect on a blood level, not a demonstrated effect on how you age.
That may turn out to matter. It hasn’t been shown to yet, and the distance between the two is the whole story of this category.
The app distinguishes reliable biomarker changes from proven outcomes, an honest line.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Camacho-Pereira J, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction. Cell Metabolism, 2016. The consumption mechanism described here.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 2018.
Frequently asked
Does NAD+ decline with age?
Yes, well-documented across research. Martens and colleagues showed chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy middle-aged and older adults. The title states the page’s point: tolerability and NAD+ elevation, not an outcome.
Do NAD+ precursor supplements raise NAD+ levels?
Yes, reliably demonstrated in trials, this part is well-established.
Does raising NAD+ improve health outcomes?
Genuinely inconsistent across small, short trials, a less settled question.
Is NMN or NR better?
Both raise measurable NAD+ markers in human studies, and neither has demonstrated a clear advantage in outcomes that matter. Choosing between them is currently a question about price and availability rather than about evidence.
Is NMN still legal to sell as a supplement?
Its status as a dietary supplement in the United States has been contested by the FDA, which affects availability from some retailers. The regulatory picture has shifted more than once, so it is worth checking the current position rather than assuming.
Do NAD+ IV drips work?
They are expensive and the evidence that they do anything beyond what oral precursors achieve is thin. The intuition that a direct infusion must be superior isn’t supported by outcome data.
Does exercise raise NAD+ levels?
There is evidence that training influences NAD+ metabolism, which is an awkward fact for the supplement framing. If the aim is supporting cellular energy metabolism, the intervention with the best evidence remains the one that is free.
What does NAD+ actually do?
It is a coenzyme central to energy production and to DNA repair processes, present in every cell. Its importance isn’t in question. What is in question is whether raising a declining level changes anything you would notice.